Jon Najarian, Najarian Family Office
Adam Jeffery | CNBC
CNBC "Halftime Report" trader Jon Najarian purchased shares of Teva Pharmaceutical Industries for his model portfolio Tuesday after spotting unusual options activity.
The company is a market leader in generic drugs with $19.7 billion in sales during 2015. Biotech and health-care stocks were lower Tuesday on negative industry sentiment after troubled Valeant Pharmaceuticals posted worse-than-expected financial guidance. Valeant shares fell by nearly half after the company's report.
Here's why Najarian bought the drug stock.
